A Study of TD-98 to Treat Symptomatic nOH in Subjects with Primary Autonomic Failure


About this study

The purpose of this study is to look at how safe TD-9855, is when taken over a longer period of time (three and a half years) to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Subjects who complete Study 0170 will be eligible for this study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Phillip Low, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer